Assessment of the nutritional status of adult patients with acute myeloid leukemia during induction chemotherapy

摘要

Abstract Objective To the best of our knowledge, few studies have evaluated the nutritional status in patients with acute myeloid leukemia (AML) during induction treatment. The aim of this retrospective study was to describe nutritional status of newly diagnosed adult patients with AML at admission and during induction chemotherapy. Methods We included consecutive newly diagnosed adult patients with AML who were admitted to the Department of Hematology (Limoges University Hospital) from April 2010 to January 2014. Nutritional assessment included body mass index (BMI) and weight loss to diagnose undernutrition. Weekly laboratory tests were collected and total energy expenditure was calculated to adapt food intake. Results Of 95 patients, 14 (15%) presented with undernutrition at admission: low BMI values ( P ??0.001) and weight loss 5% for 9.5% patients. After chemotherapy induction, 17 patients (18%) were undernutrition ( P ?=?0.05). Patients without undernutrition had a significantly lower median weight, BMI, and serum albumin level at discharge compared with their admission values ( P ??0.05); whereas their serum transthyretin levels were higher ( P ?=?0.03). They also had shorter hospital stays than patients with undernutrition (31 versus 39?d; P ?=?0.03) and longer survival at 12?mo (89.9 versus 58.3%; P ?=?0.002). Conclusions Patients with AML with good nutritional status undergoing induction chemotherapy have shorter hospital stays and longer survival. Highlights ? No consensus has been established for the use of tool for nutritional screening in intensive hematological care. ? Fifteen percent of newly diagnosed adult patients with acute myeloid leukemia presented with undernutrition at admission. ? Patients without undernutrition had shorter hospital stays and longer survival at 12 months. ? It would be interesting to adapt existing screening tools should be improved and adapted to the specific situation of induction chemotherapy in acute myeloid leukemia.